Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial
暂无分享,去创建一个
Mark Woodward | Bruce Neal | Giuseppe Mancia | Stephen MacMahon | Carol Pollock | Rohina Joshi | Sophia Zoungas | John Chalmers | Andre Pascal Kengne | M. Woodward | C. Anderson | G. Mancia | A. Kengne | N. Poulter | S. MacMahon | J. Chalmers | B. Neal | T. Ninomiya | J. Hata | H. Arima | S. Zoungas | Anushka Patel | G. Fulcher | C. Pollock | M. Adams | J. Watson | R. Joshi | Neil Poulter | Anushka Patel | Craig Anderson | Hisatomi Arima | Toshiharu Ninomiya | Jun Hata | Greg Fulcher | Mark Adams | John Watson
[1] R. Califf,et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study , 2001, Current controlled trials in cardiovascular medicine.
[2] ToshiharuNinomiya,et al. Effects of the End Point Adjudication Process on the Results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) , 2009 .
[3] C. Wilson. A study in progress. , 2008, Canadian family physician Medecin de famille canadien.
[4] S. Lehto,et al. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. , 1999, European heart journal.
[5] Advance Management Committee. Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease – preterax and diamicron MR controlled evaluation , 2001, Diabetologia.
[6] M. Woodward,et al. Effects of the End Point Adjudication Process on the Results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) , 2009, Stroke.
[7] S. Schinner,et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[8] Anushka Patel,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.
[9] S. Yusuf,et al. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs , 2009, Clinical trials.
[10] A. Hall,et al. Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. , 1993, Journal of cardiovascular pharmacology.
[11] G. Lamas,et al. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. , 2006, Contemporary clinical trials.
[12] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[13] R. Califf,et al. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. , 2002, American heart journal.
[14] C. Granger,et al. Do we need to adjudicate major clinical events? , 2008, Clinical trials.
[15] R. Califf,et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial , 2001, Current controlled trials in cardiovascular medicine.
[16] D. Cook,et al. Outcome assessment for clinical trials: how many adjudicators do we need? Canadian Lung Oncology Group. , 1997, Controlled clinical trials.